LIFECORE BIOMEDICAL, INC. DE financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data LIFECORE BIOMEDICAL, INC. DE files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	541	532	524	558	160	101	111	103	128	129
Cost of revenue	410	391	446	477	121	61.9	72.2	75.3	86.4	88.6
Gross profit	66.8	79.2	78.3	81	39.4	38.9	39.1	28	41.9	40.3
Research and development	7.23	9.47	12.8	11.5	7.58	6.68	7.84	8.74	8.58	8.26
Selling, general and administrative	46.2	52.5	52	62.1	40.7	27.7	34.7	39	40.5	44
Operating expenses	87.4	64.5	64.8	75.5	65.3	47.8	50.9	49.8	50.7
Operating income	-20.6	14.7	13.6	5.48	-25.9	-8.82	-11.8	-21.8	-8.84	-17.2
Interest expense	1.99				4.65	8.93	15.6	17.6	18.1	22.2
Interest income	0.07	0.02	0.21	0.15	0.07	0.05	0.08	0.07	0.06	0.33
Other non-operating income	1.2	0.9	2.9	1.6	-0.2	-11	0.76	-1.16	-3.05	-0
Pre-tax income	-19.7	14.2	16.4	3.64	-30.6	-29.8	-20.7	-63.9	9.51	-38.7
Income tax	-7.7	4.04	-9.36	1.52	-8.77	-6.35	-5.21	0.31	0.18	0.04
Income from continuing operations									9.33	-38.7
Net income to minority interests	0.19	0.09	0.09	0	0
Net income	-11.6	10.6	24.8	0.41	-38.2	-32.3	-117	-99.6	12	-38.7
EBITDA	-11.2	25.3	26	20.7	-7.04	11	6.27	-8.62	-0.89	-9.22
EPS, basic	-0.43	0.39	0.90	0.01	-1.31	-1.10	-3.97	-3.32	0.39	-1.27
EPS, diluted	-0.43	0.38	0.89	0.01	-1.31	-1.10	-3.97	-3.32	0.33	-1.27
Shares, basic (weighted)	27	27.3	27.5	28.4	29.2	29.3	29.5	30	30.5	34.8
Shares, diluted (weighted)	27	27.7	27.9	28.6	29.2	29.3	29.5	30	36.7	34.8

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	9.97	6	2.9	1.08	0.36	0.76	0.99	19.1	8.46	8.27
Receivables	46.4	45.9	53.9	69.6	76.2	31.6	38.3	29	31.2
Inventory	25.5	23.6	31.8	54.1	66.3	33.9	36	40.8	40	32.3
Other current assets	4.47	3.5	7.96	8.26	14.2	1.5	2.05	4.92	1.44	1.45
Total current assets	86.3	81.3	97.1	133	157	145	117	93.9	81	85.7
Property, plant and equipment	121	133	160	200	192	107	119	134	149	129
Lease right-of-use assets				0	25.3	13.5	5.55	4.28	2.44
Goodwill	49.6	54.5	54.5	76.7	33.9	13.9	13.9	13.9	13.9	13.9
Intangible assets	21.4	22.8	21.8	15.3	12.8	8.04	1.08	4.2	4.2	4.2
Other non-current assets	1.75	2.92	5.16	2.93	2.16	3.42	2.89	2.92	9.88	10.8
Total assets	343	359	405	519	294	502	275	254	254	239
Accounts payable	30.9	24.5	34.7	54	51.6	11.6	13	22.1	16.3	8.22
Accrued liabilities	5.46	7.51	9.98	10.7	9.03	7.5	8.94	4.15	22.5	22
Deferred revenue	0.83	0.31	2.63	0.5	0.35	0.29	0.92	4.1	2.11	3.42
Short-term debt	7.87	4.94	4.94	9.79	11.6	0	98.2	0.58	0.94	3.44
Total current liabilities	56.3	51.5	88.4	137	164	102	177	39.3	38.9	30.2
Long-term debt	46	42.3	37.4	87.2	101	165	0	84.3	101
Lease liabilities					22.9	20.3	9.97	6.5	1.73	1.34
Other non-current liabilities				1.74	4.55	2.87	0.19	0.17	12.1	9.74
Total liabilities	130	130	152	249	310	300	187	218	200	192
Total debt	53.8	47.2	42.3	97	113	165	98.2	84.8	125	130
Paid-in capital	137	142	142	160	163	166	167	174	178	207
Retained earnings	73.5	84.5	109	110	71.2	37.7	-79	-179	-167	-205
Other comprehensive income		0.43	1.15	0.06	-2.81	-1.36	-0.59	0
Shareholders' equity	211	227	253	270	230	202	87.8	-4.23	11.3	1.34
Minority interests	1.62	1.54
Total equity	212	228	253	270	230	202	87.8	-4.23	11.3	1.34
Total liabilities and equity	343	359	405	519	541	502	275	254	254	239
Shares outstanding	27.1	27.5	27.7	29.1	29.2	29.3	29.5	30.3	30.6	37

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-11.4	10.7	24.9	0.41	-38.2	-32.3	-117	-99.6	12	-38.7
Depreciation and amortization	9.4	10.7	12.4	15.2	18.8	19.9	18.1	13.2	7.95	8.03
Stock-based compensation	3.47	3.96	4.4	3.56	2.42	3.36	2.61	3.61	6.2	10.2
Deferred income tax	-9.78	2.53	-6.65	1.44	-1.15	-6.44	-5.59	0.25	0.16	-0.12
Change in receivables	0.07	-0.34	-7.31	-9.28	-6.36	5.78	-6.14	10.8	-3.26	-2.26
Change in inventory	-0.51	0.86	-6.53	-10.9	-12.2	-2.82	-2.18	-14.8	0.86	7.69
Change in payables	-5.28	-4.78	4.97	19.1	-1.25	-5.98	9.34	16	-6.68	-1.67
Cash from operations	20.8	29.8	19.8	16	-17	16.5	-22.6	-17.4	0.26	-0.21
Capital expenditures	-39.7	-23	-33.6	-44.7	-12.2	-19.3	-26.2		-18.4	-13.4
Acquisitions		-2.5	0	-59.9	0	0
Cash from investing	-40.4	-25.4	-35.6	-96.8	-23.9	-12.3	80	-4.81	-18.4	-6.42
Debt issued	26.7	50	0	60	27.5	170	20	150
Debt repaid	-14.7	-57.2	-5.08	-5.09	-11.1	-114	-86.4	-124	0
Stock issued	0.32	0.71	0.06	0.33	0.03	0	0	4.82	0	23.9
Cash from financing	15.4	-8.8	13.3	79	40	-3.42	-57	39.7	7.51	6.42
Net change in cash	-4.23	-4.39	-2.52	-1.75	-0.91	0.74	0.35	17.4	-10.6	-0.2
Free cash flow	-18.9	6.84	-13.8	-28.7	-29.3	-2.79	-48.8		-18.1	-13.6
Interest paid	2.02	2.33	2.29	5.61	10.1	13.2	16.9	31	2.73	1.91
Income taxes paid	2.63	2.79	0.28	-1.96	-1.12	-7.68	0.44	0.02	0.07	0.05

Key metrics

Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $4.20 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	31.3%	Gross profit / revenue.
Operating margin	-13.4%	Operating income / revenue.
EBITDA margin	-7.2%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-30.0%	Pre-tax income / revenue.
Net margin	-30.0%	Net income / revenue.
FCF margin	-10.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-0.2%	Cash from operations / revenue.
Return on equity (ROE)	-612.1%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-15.7%	Net income / average total assets.
Return on invested capital (ROIC)	-10.9%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	6.4%	Research and development expense / revenue.
SG&A / revenue	34.2%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	7.9%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	10.4%	Capital expenditures / revenue.
D&A / revenue	6.2%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	0.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	5.0%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-4.2%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-3.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	1.0%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	0.5%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-422.3%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-484.8%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	-180.2%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	-88.2%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-75.2%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-64.3%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-5.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-4.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-4.0%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-5.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	5.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.6%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.84x	Current assets / current liabilities.
Quick ratio	0.27x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.27x	(Cash + short-term investments) / current liabilities.
Debt / equity	97.6x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	54.5%	Total debt / total assets.
Liabilities / assets	80.2%	Total liabilities / total assets.
Net debt	$122.2M	Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage	-0.78x	Operating income / interest expense.
Working capital	$55.5M	Current assets - current liabilities.
Goodwill and intangibles / assets	7.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$16.7M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.52x	Revenue / average total assets.
Fixed asset turnover	0.93x	Revenue / average property, plant and equipment.
Inventory turnover	2.45x	Cost of revenue / average inventory.
Days inventory	149 days	365 x average inventory / cost of revenue.
Days payables	51 days	365 x average accounts payable / cost of revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.27	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic	-$1.27	Net income per basic share, as reported (split-adjusted).
Revenue per share	$3.70	Revenue / diluted weighted shares.
FCF per share	-$0.39	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.01	Cash from operations / diluted weighted shares.
Book value per share	$0.04	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$0.45	Tangible book value / shares outstanding.
Cash per share	$0.22	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$159.0M	Share price x shares outstanding.
Enterprise value	$281.2M	Market cap + total debt - cash - short-term investments.
P/S	1.23x	Market cap / revenue.
P/B	119x	Market cap / shareholders' equity. Only when equity is positive.
EV/Sales	2.18x	Enterprise value / revenue.
FCF yield	-8.6%	Free cash flow / market cap.
Earnings yield	-24.4%	Net income / market cap (the inverse of P/E).

What was LIFECORE BIOMEDICAL, INC. DE's revenue in fiscal 2025?

LIFECORE BIOMEDICAL, INC. DE reported revenue of $128.9M for fiscal 2025, 0.5% higher than the year before.

Was LIFECORE BIOMEDICAL, INC. DE profitable in fiscal 2025?

No. It reported a net loss of $38.7M.

How much free cash flow did LIFECORE BIOMEDICAL, INC. DE generate in fiscal 2025?

Cash from operations of $206.0K minus capital expenditures of $13.4M left free cash flow of -$13.6M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to LIFECORE BIOMEDICAL, INC. DE